Breaking News, Collaborations & Alliances

South Korean Conglomerate Invests $350M in the Center for Breakthrough Medicines

SK Inc. and CBM are partnering to hire 2,000 advanced therapy experts and build the largest manufacturer of cell and gene therapies in the world.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The Center for Breakthrough Medicines (CBM) has received $350 million in equity financing from SK Inc, South Korea’s second largest conglomerate. CBM is partnering with SK to create the world’s largest end-to-end cell and gene therapy contract development and manufacturing organization (CDMO).   CBM will leverage this investment to enhance its fully integrated pre-clinical through commercial manufacturing capabilities with world class automation and infrastructure. Existing and future capa...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters